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(UK) to € 77,854 (China) per quality adjusted life years (QALY) and € 37,361 per life 
years gained (LYG)(Europe and Canada). One French study showed an improvement 
in survival of 4 months between 2004 and 2012, with an ICER of € 54,355 per LYG, 
due to an increased use of temozolomide and bevacizumab. ConClusions: The 
literature on the cost of treatment and follow up of glioblastoma patients and on the 
cost-effectiveness of treatment modalities used in glioblastoma is scarce. Wide vari-
ations in cost are reported, probably reflecting the variation in health care systems.
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A SyStemAtiC LiterAture review of eCoNomiC BurdeN of 
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objeCtives: To characterise the economic burden of myelofibrosis and associated 
areas of unmet need. Methods: A systematic literature review was performed for 
world-wide cost-effectiveness, cost and resource studies published between January 
2004 and September 2014. Databases included MEDLINE, MEDLINE In-process, 
EconLit, EMBASE and the Cochrane Library, as well as HTA websites. Results: The 
search identified 261 cost-effectiveness and 231 cost and resource papers. Following 
two rounds of assessment, two and eight studies, respectively, were included. 
Bennett et al., 2013, reported a substantial rise in total costs from USD10,523 in the 
year prior to diagnosis to USD51,654 in the year after diagnosis. A lifetime model 
developed by El Ouagari et al., 2012, (based on COMFORT-II data) predicted lifetime 
costs of CAD494,859 and CAD421,755 for ruxolitinib and best available therapy (BAT), 
respectively. The model calculated high indirect costs due to employment absentee-
ism for patients taking ruxolitinib (CAD71,848) and BAT (CAD96,458), indicating high 
burden for patients and society. Bennett et al. reported that costs were 85% greater in 
patients with previous anaemia treatment, including transfusions. Vekeman et al., 
2015, reported that 18% of transfusion-dependant patients received iron chelation 
therapy, with significantly higher monthly pharmacy costs vs. those without (mean 
difference: $1,426, p= 0.004). El Ouagari et al. predicted lifetime transfusion costs of 
CAD18,299 for patients taking ruxolitinib and CAD13,456 for those on BAT, suggest-
ing that patients treated with ruxolitinib may experience worsening of anaemia. 
This is consistent with COMFORT-I data, which showed that transfusion-dependant 
ruxolitinib patients increased from 25% at baseline to 40% at Weeks 8-12 (Pardanani 
and Tefferi, 2014; not identified via this search). ConClusions: Myelofibrosis leads 
to significant direct costs for health systems and substantial absenteeism costs for 
patients. Despite the available treatments, patients with disease and treatment 
emergent cytopenias and transfusion dependency require additional medical man-
agement, further augmenting the economic burden.
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objeCtives: To estimate the life time CoD in metastatic colorectal cancer (mCRC) 
patients who have progressed after standard therapies, in Turkish setting. Methods: 
A panel consisting of experts held a meeting to discuss the disease management in 
mCRC. They reviewed the literature and discussed the local clinical practices. All cost 
components (anticancer medications, routine care including inpatient and outpatient 
costs and adverse event management) were evaluated. The clinical/economic param-
eters were entered as inputs of a cohort partition model mimicking the follow-up of 
patients till death. Mid-2015 local prices for medications and procedures were used as 
sources. Mid-2015 EUR currency rate (2.9274TL/EUR) was used. Results: Percentages 
of patients according to the pharmaceuticals for anticancer treatment were as follows: 
capecitabine 85%, bevacizumab 35%, 5-FU+bevacizumab 12.5%, Mod-FOLFIRINOX 7.5% 
and raltitreksed 1.5%. Other pharmacologic treatment included medications related 
with gastrointestinal symptoms (antacid, anti-diarrheal, anti-emetic), analgesics 
and opioids. Outpatient costs included oncologist visits, blood tests, imaging and 
palliative radiotherapy (in 5%). Adverse events evaluated included constitutional, 
skin, cardiac, pulmonary, gastrointestinal, blood/bone marrow, infectious, neuro-
logic and metabolic events. The components of life time CoD (2544EUR) were as fol-
lows: anticancer treatment (216EUR), other pharmaceuticals (95EUR), routine care 
(247EUR) (inpatient 120EUR + outpatients 127EUR) and adverse event management 
(5.5EUR). ConClusions: The most costly component of expenses in mCRC is anti-
cancer treatment followed by routine care costs. Especially off-label chemotherapy 
agents are constituted significant part of this routine care costs.
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objeCtives: To summarize the existing literature regarding the medical cost and 
cost-effectiveness associated with treatment and follow-up of pancreatic can-
cer. Methods: PubMed was used as search engine to retrieve publications in 
Medline, using the search terms “pancreatic cancer” AND “cost” with a publica-
tion date filter (from January 1st 2000 up to September 1st2014) and language filter 
(English). This search yielded 416 results of which 48 were relevant for this review. 
Cost were recalculated in Euros (€ ) using the June 5 2015 currency rate of $1 = € 0.8914, 
CA$1 = € 0.7131 and £1 = € 1.3667. Results: The medical cost from diagnosis to death 
of one or more stages of pancreatic cancer were reported in 8 studies conducted in 
USA (n= 3), Sweden (n= 3), Germany (n= 1) and Japan (n= 1). Four studies included 
p< 0.001; second-line treatment: coefficient 0.377, p= 0.019), pulmonary infection 
(coefficient 0.780, p< 0.001), and suppressed bone marrow function (coefficient 0.352, 
p= 0.047) were significantly associated with increased direct medical costs and urban 
resident insurance (coefficient -0.410, p< 0.001) was significantly associated with less 
direct medical costs. ConClusions: The direct medical costs associated with MM 
in publically insured Chinese patients varied substantially by treatment settings. 
Except treatment settings, complications, and comorbidities, the social economic sta-
tus associated with insurance type and residence city size have a substantial impact 
on public health resource utilization in Chinese patients with MM.
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objeCtives: Breast cancer screening has resulted in increased diagnosis of ductal 
carcinoma in situ (DCIS). Compared with other breast cancers, little is known about 
the cost of illness or quality of life burden associated with DCIS. Methods: A struc-
tured literature search strategy was developed for identifying DCIS cost and QOL data 
in three publication databases (PubMed, EMBASE, and the Cochrane Library). Primary 
and secondary search criteria were “Carcinoma, Intraductal, Noninfiltrating” or “DCIS” 
and “Quality of life” or “Costs” or “Resource use”, respectively. Publications for review 
were restricted to those published between 2004 and 2014 inclusive. Abstract screen-
ing was performed by a single reviewer, with included results checked for protocol 
alignment by two further reviewers. Results: In total, 585 articles were identified 
for review, of which 55 were duplicates between databases. Following abstract review, 
111 articles were retained for analysis. The majority of excluded articles were not 
specific to DCIS or did not report cost or QOL data. DCIS does not directly affect QOL. 
Anxiety caused by DCIS diagnosis is a key decrement to QOL, although its impact can 
be transient. Longer term impacts on body image and role limitation were apparent 
following surgical intervention. Evidence of QOL detriments due to DCIS treatment 
were identified. Use of post-surgical radiotherapy is increasing, and patients receiving 
lumpectomy plus radiotherapy had significantly lower ‘mental health’ (74.0 vs. 77.4) 
and ‘vitality’ (59.3 vs. 63.5) QOL than controls. There is little data on the cost burden 
of DCIS. Individual cost items were identified, with radiotherapy estimated at USD 
10,700 to 34,900. ConClusions: Anxiety about tumour recurrence and body image 
and treatment side effects are the major factors influencing patient QOL in DCIS. 
Adverse events and costs associated with DCIS treatments makes the choice of treat-
ment pathway important for both patients and healthcare providers.
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objeCtives: Cervical cancer, caused by oncogenic Human Papillomavirus (HPV) 
types, is in Croatia the tenth most common cancer in women and accounted for 106 
women deaths in 2012. The aim of this study was to evaluate the costs associated 
with the diagnostic and treatment of cervical cancer and cervical intraepithelial 
neoplasia in Croatia in 2012. Methods: Publicly available data on the costs related 
to cervical cancer and cervical intraepithelial neoplasia diagnostic and treatment 
were collected. The main sources for the number of cases were the Croatian Institute 
of Public Health Yearbook for 2012 and Croatian Cancer Registry data. For the unit 
cost, the list of Diagnosis-Related Groups codes was used. When country-specific 
information was unavailable, reference to international data was used. Total cost 
was calculated by multiplying the number of cases with unit cost. Only direct medi-
cal costs were taken into consideration, using governmental perspective. Results: 
In 2012, cervical cancer and cervical intraepithelial neoplasia amounted to a total 
cost of € 5,418,790.70. Papanicolaou (Pap) smear tests represent the major source of 
expenditure with a total cost of € 2,367,686.92. A total of 374,484 Pap smear tests were 
carried on in 2012, from which 7.3% were pathological. ConClusions: Cervical 
cancer and cervical intraepithelial neoplasia caused by high risk oncogenic HPV-
types represent an important health and economic burden in Croatia. The results 
of this analysis may be useful to assess the potential reduction in cost associated 
with HPV-related diseases if additional prevention strategies were implemented.
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objeCtives: To summarize the existing literature regarding the medical cost associ-
ated with treatment and follow-up of glioblastoma. Methods: PubMed was used 
as search engine to retrieve publications in Medline using the search terms “(glio-
blastoma) AND (cost)” with a publication date filter (from January 1st 2000 up to 
September 1st2014) and language filter (English). This search yielded 107 publica-
tions of which 14 were relevant for this review. Costs were recalculated in Euros 
(€ ) using the June 5 2015 currency rate of $1 = € 0.8914, CA$1 = € 0.7131 and 1£ = 
€ 1.3667. Results: Two studies calculated the average total medical cost of glioblas-
toma treatment including direct hospital centered costs from diagnosis to death 
and one study included healthcare payer perspective cost from diagnosis to two 
years of follow-up. The cost ranged between € 12,229 - € 43,894 (median: € 39,000). Two 
studies calculated the average cost of the combination of surgery and chemoradio-
therapy which varied from € 16,007 per patient in Canada to € 41,744 per patient in 
Switzerland. The addition of temozolomide to radiotherapy prolongs survival and 
improves quality of life. The incremental cost-effectiveness ratio (ICER) of temozo-
lomide plus radiotherapy as compared to radiotherapy alone ranged from € 49,054 
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Age-standardized incidence rates for PC ranged from 4.5 to 170.2 cases per 100,000 
males per year, and was 110.8 per 100,000 males per year in the EU. The annual per-
centage increase in PC ranged from 2.8% in Australia to 8.6% in China. The cost of 
PC management in Europe was highest in France (EUR 722 million). Key cost drivers 
were identified as the initial year of care, radical prostatectomy, and terminal care. 
Compared with other EU countries, higher use of radical prostatectomy and lower use 
of active surveillance in France result in a higher cost burden. ConClusions: The 
incidence of PC is increasing in the majority of countries with data available. The cost 
of illness is rising accordingly, and the cost differential between active surveillance 
and intervention is substantial. Selecting the optimal treatment per patient is likely 
to be an important aspect in limiting the increase in the PC burden.
PCN113
ePidemioLoGy ANd BurdeN of muLtiPLe myeLomA iN JAPAN: A 
SyStemAtiC review
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objeCtives: Bortezomib (BOR), lenalidomide (LEN), thalidomide (THAL) are avail-
able to patients with multiple myeloma (MM) in Japan, and new drugs are also to 
be launched. Introduction of Health Technology Assessment in FY2016 is aimed in 
Japan. The severity and its expensive treatment cost of MM disease may become 
important subjects to be discussed although a lack of resources for assessing cost-
effectiveness of treatment has been pointed out in Japan. The objective of this study 
was to sort epidemiological data and information on currently available treatments 
for MM through a systematic review and to estimate an expected total medical cost 
for relapsed/refractory MM (RRMM) patients. Methods: The literature search was 
conducted in MEDLINE and Ichushi-Web. Eligible studies were those of Japanese 
patients and published in the past 10 years. Studies were assessed for the followings: 
incidence and prevalence rate, number of patients, mortality rate, development rate 
of acute myelogenous leukemia (AML), and clinical effectiveness of current therapies. 
Expected total medical cost per RRMM patient was calculated from a model with 
overall survival and progression-free survival of RRMM patients based on literature 
review, assuming salvage therapies were comprised of BOR, LEN, and THAL. Results: 
Annual incidence and 5-year prevalence rates of MM were reported as 1.3 to 5.4 and 
9.7 per 100,000 persons, respectively. Although mortality rates were reported, data 
on AML development of MM patients tended to lack. Clinical trials of BOR and THAL-
based treatments were found, while there was only one for LEN-based treatment. 
An expected total medical cost for RRMM patient was estimated to be over € 100,000 
(1,383,000 yen). ConClusions: While the study indicated large medical resources 
usage of MM and the necessity of cost-effective evaluation for MM treatments, few 
studies have revealed its burden. Further studies on current situation surrounding 
MM treatments are expected.
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objeCtives: Gastrointestinal stromal tumors (GIST) are rare but costly tumors 
with an estimated incidence of 1.5/100 000/year in Europe. Granting reimburse-
ment requires locally adapted cost effectiveness data in Turkey. This study was con-
ducted to estimate the costs-of disease and direct cost components of metastatic/
inoperable GISTs that did not respond to prior imatinib mesylate and sunitinib 
malate. Methods: Bayer Turkey Market Access team organized an “expert panel” 
composed of oncologists to discuss the local treatments, routine monitoring and 
adverse event management algorithms in metastatic/inoperable GIST patients. The 
panel reviewed the global and local literature and guidelines and also discussed 
the spectrum of frequently performed local clinical practices. All cost components, 
including medications, hospitalization, out-patient follow-up procedures and reha-
bilitation services were reviewed. End of 2014 local prices for medications and pro-
cedures were used as sources. Based on the answers of the physicians, the cost of 
healthcare resources regarding the conditions described were calculated from the 
perspective of the Turkish payer (SSI – Social Security Institution). Results: In met-
astatic/inoperable GIST patients, treatment should be continued indefinitely, since 
treatment interruption is generally followed by relatively rapid tumor progression 
in almost all cases, even when lesions have been previously surgically excised. The 
cost of routine monitoring in the follow-up of metastatic/inoperable GIST patients 
was estimated to be 62.40 TL/month during progression-free and post-progression 
periods, while it was 490.00 TL/month during the terminal phase. The greatest cost 
is estimated for hospitalization in the intensive care unit ranging from 200.00 to 
800.55 TL per incident. The most common adverse reactions were listed as hand and 
foot skin reaction (4%) and diarrhea (6.7%). ConClusions: The costs of the disease, 
which therefore are quite high, estimated here will provide the most reliable data 
reflecting current figures to Public Stakeholders. Despite these high expenditures, 
those treatments’ efficacy is not clinically proven.
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objeCtives: To analyze the inpatients direct medical costs and reimbursement 
rate of breast cancer based on national claimed database for urban employees and 
compare on the cost of different types of treatment. Methods: Mechanical sam-
costs from a hospital centered view and four studies included costs from a third 
party payer view. Overall, the mean total treatment cost of pancreatic cancer treat-
ment ranged from € 8,037 to € 38,232 per patient. The cost of resectable disease ranged 
from € 19,890 to € 120,071 per patient. The cost of unresectable disease ranged from 
€ 14,899 to € 58,208. The cost of metastatic disease ranged from € 13,873 to € 43,679. 
The cost of laparoscopic distal pancreatectomy ranged from € 9,603 per patient to 
€ 15,433 per patient. The cost of open distal pancreatectomy ranged from € 10,944 per 
patient to € 22,790 per patient. 15 studies reported cost-effectiveness data. The incre-
mental cost-effectiveness ratio (ICER) of folfirinox compared to gemcitabine ranged 
from € 48,637 per quality adjusted life years (QALY) to € 62,657 per QALY. The ICER of 
surgery followed by chemotherapy compared to surgery alone ranged from € 34,636/
QALY to € 81,971/QALY. ConClusions: Surgery is an important cost-driving factor in 
pancreatic cancer treatment. Wide variations in cost are reported, probably reflecting 
the variation in health care systems.
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objeCtives: A 2014 study by Bhaskaran et al. found that an increase in BMI was asso-
ciated with an increased risk of cancer in 10 sites. The National Health Service (NHS) 
England cancer related expenditure for the cancers in these 10 sites from Bhaskaran 
et al. accounted for £2.78 billion in 2012/13. This study estimated the increasing cost 
burden of these cancers to NHS England relative to increasing BMI. Methods: The 
analysis used the primary care trust (PCT) expenditure for the financial year 2012/13 
of NHS England. The 10 cancers found by Bhaskaran et al. whose incidences increase 
as BMI increases were linked to the ‘cancers and tumours’ category of the cancer 
expenditure. We calculated the cancer expenditure attributable to obesity for each of 
the 10 cancers using risks reported by Bhaskaran et al. Bhaskaran et al. also reported 
hazard ratios (HRs) for incidence of each cancer for a 5kg/m2 increase in BMI – we 
used these HRs to estimate the increased cost of each of the 10 cancers for increase 
in population BMI. Results: We calculated that the 2012/13 cost burden of the 10 
cancers attributable to obesity was £0.32 billion. If the mean population-wide BMI 
increased by 5 kg/m2 we estimated that the cost burden of 10 cancers attributable to 
obesity would have increased to £0.41 billion from £0.32 billion in 2012/13. The cost 
burden would increase most dramatically for uterus cancer, with a predicted increase 
of 62%. ConClusions: Cancers attributable to obesity have a high cost burden. A 
population-wide increase in BMI would result in higher incidence of 10 cancers. The 
cost to NHS England would increase dramatically, with the required budget increasing 
by more than 25% for an increase in BMI of 5kg/m2.
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objeCtives: To summarize the existing literature regarding the medical cost associ-
ated with treatment and follow-up of head and neck cancer. Methods: PubMed 
was used as search engine to retrieve publications in Medline using the search term 
“(head and neck cancer) AND (cost)” with a publication date filter (from January 1st 
2000 up to September 1st 2014) and language filter (English). This search yielded 
2,635 publications of which 97 were relevant for this review. Cost were recalculated 
in Euros (€ ) using the June 5 2015 currency rate of $1 = € 0.8914. Results: In six stud-
ies total treatment cost from diagnosis to discharge ranged from € 15,214 per patient 
to € 21,665 per patient. In four studies total medical cost including treatment and 
follow-up ranged from € 29,434 per patient to € 76,277 per patient. The reconstruction 
cost ranged from € 8,797 per patient to € 48,115 per patient. In three studies the cost 
of surgery performed by a high-volume surgeon ranged from € 7,869 per patient to 
€ 24,233 per patient and by a low-volume surgeon ranged from € 9,146 per patient to 
€ 22,067 per patient. In two studies the median cost for stage I disease ranged from 
€ 3,264 per patient to € 11,205 per patient, for stage II disease ranged from € 5,230 per 
patient to € 20,473 per patient, for stage III disease ranged from € 9,196 per patient 
to € 28,429 per patient and for stage IV disease ranged from € 10,222 per patient to 
€ 45,373 per patient. In three studies the Incremental Cost effectiveness Ration (ICER) 
of cetuximab plus radiotherapy compared to radiotherapy alone ranged from € 7,530 
per QALY to € 14,624 per QALY. ConClusions: The literature on the costs associated 
with the treatment of head and neck cancer is extensive. Wide variations in cost are 
reported, probably reflecting the variation in health care systems.
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objeCtives: Screening programs have resulted in prostate cancer (PC) diagnoses 
increasing and being made both earlier in the disease state and the patient’s life. 
Understanding the clinical and cost burden of PC and its associated treatment options 
is imperative for optimization of healthcare resources. Methods: A structured lit-
erature review of three publication databases (PubMed, EMBASE, and the Cochrane 
Library) was undertaken. Literature review was focused on publications with a major 
focus on “Prostatic Neoplasms” or containing the term “Prostate Cancer”. Secondary 
search criteria restricted results to contain information on epidemiology, cost of ill-
ness, adverse events, or treatment protocols. To ensure that recent estimates and 
practice guidelines were evaluated, literature was restricted to those published on 
or after January 1, 2009. Abstract screening selected publications reporting data from 
European countries and other nations with developed healthcare systems. Results: 
